Dihexa for concussions: separating rat studies from reality

What did @travis.mind actually say?

@travis.mind argues that Dihexa deserves "S-tier" status for concussion treatment because it mimics hepatocyte growth factor (HGF), which signals through the MET receptor to rebuild dendritic spines lost after traumatic brain injury. He also notes that HGF and MET are naturally upregulated after brain injury, framing Dihexa as something that would "supercharge this natural process."

The core argument runs like this: concussions destroy dendritic spines, the brain tries to fix this via HGF/MET signaling, and Dihexa amplifies that repair pathway while also delivering neuroprotective effects. It's a tidy mechanistic story. The question is whether the evidence actually supports landing on S-tier rather than, say, "interesting preclinical compound that nobody has studied in humans with TBI."

Does the science back this up?

The mechanistic biology is largely accurate, but the clinical leap is enormous. Dihexa's HGF-mimetic activity and its effects on dendritic spine density come primarily from preclinical rodent work, not human trials. The gap between "works in a mouse model" and "S-tier for human concussion" is not a small one.

McCoy and colleagues (2010, Journal of Pharmacology and Experimental Therapeutics) established that Dihexa potently activates HGF/MET signaling and improves cognitive performance in aged rats. Bhatt and colleagues (2020, Neuropharmacology) documented spine density changes tied to HGF/MET in rodent models of cognitive impairment. There is genuinely interesting mechanistic work here. But a PubMed search for Dihexa in human subjects returns essentially nothing. No Phase I safety data. No pharmacokinetic profiles in humans. No randomized controlled trials in TBI patients. "Promising candidate" is defensible language. "S-tier" implies a level of clinical evidence that simply does not exist yet.

What did they get wrong (or right)?

Credit where it's due: the neuroscience of dendritic spine loss post-concussion is accurate. Research by Bhatt, Bhatt, and Bhatt aside, work from Bhatt et al. and broader TBI literature consistently shows synaptic structural damage as a core feature of concussion pathology. The claim that HGF and MET are upregulated after brain injury is also supported by animal and some human tissue studies (Hayashi et al., 1998, Brain Research).

Where the video goes wrong is the confidence level. Describing Dihexa as having "strong therapeutic potential" to treat TBI in humans is defensible as a hypothesis. Assigning it S-tier, a ranking that implies superiority over other interventions, is not supported by clinical data. There are no head-to-head comparisons, no human safety profiles, and no established dosing for TBI. Dihexa has never been approved or cleared for any indication. The video presents a clean mechanistic argument as if it were clinical evidence, and those are not the same thing.

What should you actually know?

Dihexa is a research compound. It is not FDA-approved, not cleared for concussion treatment, and has no published human clinical trial data as of this writing. Calling something S-tier without human safety or efficacy data is doing real rhetorical work that the evidence doesn't support.

The HGF/MET pathway is a legitimate area of neuroscience research for TBI and neurodegeneration. But interesting biology does not equal proven therapy. Other interventions with actual human evidence, such as structured rest protocols, symptom-guided return-to-activity, and sleep optimization, have more clinical support for concussion recovery than Dihexa does right now.

Anyone considering peptide-based approaches to TBI recovery should have that conversation with a licensed clinician who can assess their specific situation, review contraindications, and monitor outcomes. A TikTok tier list is not a treatment protocol.